2',3'-Dideoxyadenosine
Names
[ CAS No. ]:
4097-22-7
[ Name ]:
2',3'-Dideoxyadenosine
[Synonym ]:
DDA
((2S,5R)-5-(6-Amino-9H-purin-9-yl)tetrahydrofuran-2-yl)methanol
[(2S,5R)-5-(6-aminopurin-9-yl)oxolan-2-yl]methanol
Dideoxyadenosine
Didanosine impurity G
6-Amino-9-(2',3'-dideoxy-b-D-glycero-pentofuranosyl)purine
EINECS 223-853-2
[(2S,5R)-5-(6-Amino-9H-purin-9-yl)tetrahydrofuran-2-yl]methanol
2-furanmethanol, 5-(6-amino-9H-purin-9-yl)tetrahydro-, (2S,5R)-
2',3'-Dideoxyadenosine
9-(2,3-Dideoxy-β-D-ribofuranosyl)adenine
MFCD00010534
9-(2,3-Dideoxy-beta-D-ribofuranosyl)adenine
[(2S,5R)-5-(6-Amino-9H-purin-9-yl)tetrahydro-2-furanyl]methanol
Biological Activity
[Description]:
[Related Catalog]:
[Target]
HIV[1]
[In Vitro]
[References]
Chemical & Physical Properties
[ Density]:
1.8±0.1 g/cm3
[ Boiling Point ]:
539.1±60.0 °C at 760 mmHg
[ Melting Point ]:
181-184 °C(lit.)
[ Molecular Formula ]:
C10H13N5O2
[ Molecular Weight ]:
235.242
[ Flash Point ]:
279.9±32.9 °C
[ Exact Mass ]:
235.106918
[ PSA ]:
99.08000
[ LogP ]:
-0.43
[ Vapour Pressure ]:
0.0±1.5 mmHg at 25°C
[ Index of Refraction ]:
1.822
[ Storage condition ]:
2-8°C
MSDS
Toxicological Information
CHEMICAL IDENTIFICATION
- RTECS NUMBER :
- AU7358900
- CHEMICAL NAME :
- Adenosine, 2',3'-dideoxy-
- CAS REGISTRY NUMBER :
- 4097-22-7
- BEILSTEIN REFERENCE NO. :
- 0619924
- LAST UPDATED :
- 199612
- DATA ITEMS CITED :
- 11
- MOLECULAR FORMULA :
- C10-H13-N5-O2
- MOLECULAR WEIGHT :
- 235.28
HEALTH HAZARD DATA
ACUTE TOXICITY DATA
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 5 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- >500 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Subcutaneous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 1320 mg/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 19600 mg/kg/28D-I
- TOXIC EFFECTS :
- Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Blood - changes in erythrocyte (RBC) count Nutritional and Gross Metabolic - weight loss or decreased weight gain
MUTATION DATA
- TEST SYSTEM :
- Rodent - mouse
- DOSE/DURATION :
- 9 gm/kg/3D (Continuous)
- REFERENCE :
- EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987- Volume(issue)/page/year: 18,168,1991
Safety Information
[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
[ Hazard Codes ]:
C
[ Risk Phrases ]:
R34
[ Safety Phrases ]:
26-27-36/37/39-45
[ RIDADR ]:
NONH for all modes of transport
[ WGK Germany ]:
2
[ RTECS ]:
AU7358900
[ HS Code ]:
2934999090
Synthetic Route
Precursor & DownStream
Precursor
DownStream
Customs
[ HS Code ]: 2934999090
[ Summary ]:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Articles
Biochem. Biophys. Res. Commun. 464 , 168-75, (2015)
Iron chelation is a promising therapeutic strategy for cancer that works, in part, by inducing overexpression of N-myc downstream-regulated gene 1 protein (NDRG1), a known growth inhibitor and metasta...
The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients.Cancer Res. 75(1) , 16-21, (2015)
Identifying modifiers of glioma risk in patients with type I neurofibromatosis (NF1) could help support personalized tumor surveillance, advance understanding of gliomagenesis, and potentially identif...
Metformin as adjunct antituberculosis therapy.Sci. Transl. Med. 6(263) , 263ra159, (2014)
The global burden of tuberculosis (TB) morbidity and mortality remains immense. A potential new approach to TB therapy is to augment protective host immune responses. We report that the antidiabetic d...